Ozmosi | Mequitazine Drug Profile

Product Description

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Pierre Fabre
Company Location: Europe
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Rhinitis, Allergic, Seasonal|Chikungunya Fever

Phase 2: Rhinitis, Allergic, Seasonal|Overactive Bladder|Asthma

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
2013-002517-35	2013-002517-35	P2	Completed	Asthma	2014-04-22	2022-03-13	Treatments
2010-024271-10	2010-024271-10	P2	Terminated	Overactive Bladder	2011-09-14	2022-03-13	Treatments
2005-005975-13	2005-005975-13	P2	Completed	Rhinitis, Allergic, Seasonal	2006-08-14	2022-03-12	Treatments
2008-001860-36	2008-001860-36	P3	Completed	Rhinitis, Allergic, Seasonal	2013-05-29	2022-03-12	Patient Enrollment\|Treatments
2006-006165-17	2006-006165-17	P3	Active, not recruiting	Chikungunya Fever	2007-12-20	2025-06-26	Treatments
2006-006947-30	2006-006947-30	P3	Completed	Rhinitis, Allergic, Seasonal	2007-07-25	2022-03-12	Treatments

Recent News Events

Date	Type	Title
08/29/2022	PubMed	Experimental verification and validation of immune biomarkers based on chromatin regulators in ischemic stroke.
08/01/2021	PubMed	Chiral separation and molecular simulation study of six antihistamine agents on a coated cellulose tri-(3,5-dimethylphenycarbamate) column (Chiralcel OD-RH) and its recognition mechanisms.
04/01/2020	PubMed	Second-generation antihistamines: a study of poisoning in children.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Mequitazine

Alternative Names: mequitazine Clinical Status: Inactive Latest Update: 2022-08-29 Latest Update Note: PubMed Publication